The BRAF-inhibitor PLX4720 inhibits CXCL8 secretion in BRAFV600E mutated and normal thyroid cells: a further anti-cancer effect of BRAF-inhibitors

[1]  M. Rotondi,et al.  Role of Chemokines in Thyroid Cancer Microenvironment: Is CXCL8 the Main Player? , 2018, Front. Endocrinol..

[2]  R. Franco,et al.  Interleukin‐8, but Not the Related Chemokine CXCL1, Sustains an Autocrine Circuit Necessary for the Properties and Functions of Thyroid Cancer Stem Cells , 2017, Stem cells.

[3]  A. Balduini,et al.  Effect of Interferon-γ on the Basal and the TNFα-Stimulated Secretion of CXCL8 in Thyroid Cancer Cell Lines Bearing Either the RET/PTC Rearrangement Or the BRAF V600e Mutation , 2016, Mediators of inflammation.

[4]  Duane H. Hamilton,et al.  The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance , 2016, Vaccines.

[5]  M. Rotondi,et al.  Normal human thyroid cells, BCPAP, and TPC-1 thyroid tumor cell lines display different profile in both basal and TNF-α-induced CXCL8 secretion , 2016, Endocrine.

[6]  A. Balduini,et al.  TNF-α increases the membrane expression of the chemokine receptor CCR6 in thyroid tumor cells, but not in normal thyrocytes: potential role in the metastatic spread of thyroid cancer , 2016, Tumor Biology.

[7]  R. Franco,et al.  Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8–Akt–Slug pathway , 2015, Oncogene.

[8]  M. Rotondi,et al.  Metformin reverts the secretion of CXCL8 induced by TNF-α in primary cultures of human thyroid cells: an additional indirect anti-tumor effect of the drug. , 2015, The Journal of clinical endocrinology and metabolism.

[9]  Weiqing Wang,et al.  Tumor-associated macrophages promote the metastatic potential of thyroid papillary cancer by releasing CXCL8. , 2014, Carcinogenesis.

[10]  M. A. Marcello,et al.  The role of the inflammatory microenvironment in thyroid carcinogenesis. , 2014, Endocrine-related cancer.

[11]  Huang,et al.  Tumor-associated macrophages promote the metastatic potential of thyroid papillary cancer by releasing CXCL8. , 2014, Carcinogenesis.

[12]  M. Rotondi,et al.  CXCL8 in thyroid disease: from basic notions to potential applications in clinical practice. , 2013, Cytokine & growth factor reviews.

[13]  M. Rotondi,et al.  Type I and type II interferons inhibit both basal and tumor necrosis factor-α-induced CXCL8 secretion in primary cultures of human thyrocytes. , 2013, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[14]  A. Viale,et al.  Relief of Feedback Inhibition of Her3 Transcription by Raf and Mek Inhibitors Attenuates Their Antitumor Effects in Braf -mutant Thyroid Carcinomas Human Oncology and Pathogenesis Program, Pathology, And , 2022 .

[15]  P. Ladenson,et al.  Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. , 2013, JAMA.

[16]  A. Balduini,et al.  Discoidin Domain Receptor 1 Protein Is a Novel Modulator of Megakaryocyte-Collagen Interactions* , 2013, The Journal of Biological Chemistry.

[17]  M. Rotondi,et al.  Interferon-γ and tumor necrosis factor-α sustain secretion of specific CXC chemokines in human thyrocytes: a first step toward a differentiation between autoimmune and tumor-related inflammation? , 2013, The Journal of clinical endocrinology and metabolism.

[18]  R. Melillo,et al.  Inflammation in thyroid oncogenesis. , 2012, American journal of cancer research.

[19]  Kinam Park,et al.  Targeted drug delivery to tumors: myths, reality and possibility. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[20]  Marianne D. Castillo,et al.  IL-8 signaling plays a critical role in the epithelial-mesenchymal transition of human carcinoma cells. , 2011, Cancer research.

[21]  C. Nucera,et al.  BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. , 2011, Cancer research.

[22]  A. Fischer,et al.  Targeting BRAFV600E with PLX4720 Displays Potent Antimigratory and Anti-invasive Activity in Preclinical Models of Human Thyroid Cancer , 2011, The oncologist.

[23]  T. Giordano,et al.  B-RafV600E and thrombospondin-1 promote thyroid cancer progression , 2010, Proceedings of the National Academy of Sciences.

[24]  B. Haugen,et al.  Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. , 2010, The Journal of clinical endocrinology and metabolism.

[25]  M. Santoro,et al.  Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. , 2009, The Journal of clinical endocrinology and metabolism.

[26]  C. Nucera,et al.  A novel orthotopic mouse model of human anaplastic thyroid carcinoma. , 2009, Thyroid : official journal of the American Thyroid Association.

[27]  M. McMahon,et al.  Oncogenic BRAFV600E inhibits BIM expression to promote melanoma cell survival , 2008, Pigment cell & melanoma research.

[28]  A. Pinchera,et al.  BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. , 2008, The Journal of clinical endocrinology and metabolism.

[29]  Jianmei Wei,et al.  A novel B-RAF inhibitor blocks interleukin-8 (IL-8) synthesis in human melanoma xenografts, revealing IL-8 as a potential pharmacodynamic biomarker , 2008, Molecular Cancer Therapeutics.

[30]  M. Loda,et al.  BRAF(V600E) mutation and the biology of papillary thyroid cancer. , 2008, Endocrine-related cancer.

[31]  Kam Y. J. Zhang,et al.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.

[32]  D. Peeper,et al.  BRAFE600 in benign and malignant human tumours , 2008, Oncogene.

[33]  S. Asa,et al.  Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas. , 2007, Human pathology.

[34]  M. Xing,et al.  BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. , 2007, Endocrine reviews.

[35]  M. Xing,et al.  BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. , 2007, The Journal of clinical endocrinology and metabolism.

[36]  P. Beck‐Peccoz,et al.  BRAF mutations in an Italian cohort of thyroid cancers , 2004, Clinical endocrinology.

[37]  T. Kawabe,et al.  Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. , 2003, Cancer research.

[38]  G. Francis,et al.  Papillary thyroid carcinomas from young adults and children contain a mixture of lymphocytes. , 2003, The Journal of clinical endocrinology and metabolism.

[39]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[40]  Shinichiro,et al.  Carcinoma , 1906, The Hospital.